Showing 91-100 out of 123
Page 10 of 13« First«...89101112...»Last »
KONFIDENT Phase 3 Trial Design for Sebetralstat (KVD900), a Novel Investigational Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angloedema AttacksLumry WR, Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA, Audhya PK, Smith MD, Yea CM, Riedl MA, Maurer M
EAC 2022
Agreement Between Improvements in Patient Global Impression of Change and Other Measures of Improvement and Attack Resolution Observed in a Phase 2 Trial With Sebetralstat (KVD900) in Patients With Hereditary AngioedemaAudhya P, Smith MD, Williams P, Yea CM, Cohn DM
EAC 2022
Oral Sebetralstat (KVD900) Provides Rapid Inhibition of Plasma Kallikrein and Fast Improvement in Attack Symptoms in Patients With Hereditary AngioedemaSmith MD, Duckworth EJ, Hampton SL, Yea CM, Audhya P, Feener EP
EAC 2022
Agreement of Patient Global Impression of Change With Attack Resolution or Use of Rescue Medication in Patients With Hereditary AngioedemaAudhya P, Williams P, Yea C, Cohn D
AAAAI 2022
Rapid Plasma Kallikrein Inhibition Following Oral KVD900 Is Associated With Early Symptom Relief in Patients With Hereditary AngioedemaDuckworth EJ, Feener EP, Yea CM, Audhya P, Hampton SL, Smith MD
AAAAI 2022
KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study resultsMaetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM
PMID: 35086692
Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP
Clinical & Experimental Allergy
Relationship Between PGI-C Scale and Other PROs in KVD900 Trial in Hereditary AngioedemaAudhya P, Williams P, Yea CM
ACAAI 2021
A single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE): Results of a phase 2, placebo-controlled, double-blind cross-over trialAygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Grivcheva-Panovska V, Kiani-Alikhan S, Krcmova I, Bernstein J, Manning M, Stroud C, Hanzlikova J, Li HH, Longhurst HJ, Melamed IR, Young P, Feener E, Iverson M, Maetzel A, Morten RM, Smith MD, Watissée MI, Williams P, Yea CM, Maurer M, Banerji A, and Riedl MA
EAACI 2021
Prevalence of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physiciansRiedl MA, Danese M, Danese S, Ulloa J, and Maetzel A
EAACI 2021
